Wave Neuroscience Announces FDA Clearance of MeRT for PTSD
Summary
Wave Neuroscience announced that the FDA granted clearance for its MeRT System, representing the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for Post-Traumatic Stress Disorder. MeRT, or Magnetic EEG-guided Resonance Therapy, uses a patient's own brain data to inform highly personalized treatments. The clearance was supported by a double-blinded randomized controlled multisite trial conducted with Texas A&M Health Institute that demonstrated significant reductions in PTSD symptom severity.
Why it matters
This FDA clearance establishes an entirely new category in precision mental healthcare and represents a major regulatory milestone for biomarker-guided neuromodulation. By moving beyond one-size-fits-all approaches to personalize treatment based on individual neurophysiology, MeRT could catalyze broader adoption of data-driven, individualized approaches to treating complex neuropsychiatric conditions including PTSD, which affects millions of veterans, first responders, and trauma survivors.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial